10x Genomics (TXG) Preferred Stock Liabilities (2018 - 2019)

10x Genomics has disclosed Preferred Stock Liabilities across 2 years of filings, most recently posting $243.2 million for Q2 2019.

• Preferred Stock Liabilities for Q2 2019 came in at $243.2 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2019 was $243.2 million (changed N/A YoY), and the FY2018 annual result was $243.2 million, up 53.55% from the prior year.
• Preferred Stock Liabilities came in at $243.2 million for Q2 2019 at 10x Genomics, roughly flat from $243.2 million in the prior quarter.
• In the past five years, Preferred Stock Liabilities ranged from a high of $243.2 million in Q4 2018 to a low of $208.3 million in Q3 2018.